Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide inMonotherapy A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

METHODSdRandomized, double-blind, 12-week study of 361 patients not on glucose-lowering therapy (HbA1c 7–10%) allocated to one of four once-daily subcutaneous dose increase regimens: lixisenatide 2-step (10mg for 1week, 15mg for 1week, and then 20mg; n = 120), lixisenatide 1-step (10 mg for 2 weeks and then 20 mg; n = 119), placebo 2-step (n = 61), or… (More)